METHOD & SOURCES

How this CRO comparison uses sources and dates

The original comparison has 39 vendor statements across 16 CROs. This review adds 6 source-linked statements covering therapeutic scope, ICON general operations and Medpace’s team-continuity claim. See the new source records. Every claim is vendor-authored; none demonstrates study-specific outcomes, ClinicalTrials.gov trial counts, named team capacity, or trial pricing. Shared limits apply across every page rather than being repeated in every comparison cell.

Why some cells are marked unknown

When a reviewed CRO page covers only one offering (for example, IQVIA’s Phase IIb/III service page or ICON’s Accellacare in-home page) or summarizes only high-level corporate positioning (for example, Premier Research’s homepage), missing fields are marked as not stated or not detailed on the reviewed page rather than inferred from general reputation or third-party directories.

Sources, read dates, and exact hashes

Change review guard

The build compares current accepted fact and source-snapshot hashes against a retained baseline (accepted-evidence.json) before writing pages or dependency bindings. A changed or missing accepted input writes a review queue and stops the build while preserving the accepted baseline until review. No automatic scheduler is installed.

← Back to CRO overview

Sources for the added answers

Download the added facts (JSON)

IQVIA · Therapeutic and Specialty Expertise

Open primary source ↗

Read 2026-11-14T03:56:44.432492+00:00 · Vendor documentation · Explicit FAQ list read beyond navigation; broad company scope, not study-specific evidence.
Saved capture SHA-256: 62f9cd25b56159fef22b58b8cab99a98e7be9feca4eb062a4c1112a876a60aac

Passages used
  • therapeutic area evidence: FAQ L643–L645

ICON · Clinical and Scientific Operations

Open primary source ↗

Read 2026-11-14T03:56:44.426308+00:00 · Vendor documentation · General Phase 2–3 clinical operations, separate from Accellacare in-home offering.
Saved capture SHA-256: c0aaad4b280ab5515db09d6167ce8ea1e29a85736cac7f594be5341d171b796b

Passages used
  • phase evidence: L1–L3
  • therapeutic area evidence: L37–L40
  • service scope: L37–L40

Medpace · About Medpace

Open primary source ↗

Read 2026-11-14T03:56:44.432492+00:00 · Vendor documentation · Explicit therapeutic FAQ and team-continuity claim; no independently verified team allocation or turnover comparison.
Saved capture SHA-256: 648e644e0357c50d0d35f6a7601a7c83178d504373d5b6877ac610e9859b1316

Passages used
  • therapeutic area evidence: FAQ L202–L229
  • team continuity claim: L234–L236